DR-70, A promising biomarker for the detection of lung cancer>

Introduction: Lung cancer is characterized by an aggressive phenotype with a high mortality rate, early metastasis, and proliferation rate. Treatment options and prognosis differ significantly at each stage. Various noninvasive imaging studies and invasive tests are available. However, the diagnosis of the disease is in the late stage. Therefore, it is essential to find biomarkers for the early detection of lung cancer. Material and Methods: Between 2018 and 2020, 73 lung cancer patients and 71 healthy volunteers with the same demographic characteristics were included in our study. DR-70 level was measured by a photometric method in serum samples taken from all volunteers. Results: A total of 144 volunteers (110 male, 34 female) were included in the study. DR-70 levels in the lung cancer group (2.53±2.64 µg/mL) were found to be statistically significantly higher than the healthy control group (0.56±1.23 µg/mL). Clinical sensitivity and specificity of DR-70 for lung cancer were found to be 87.67% and 88.73%. Conclusion: In patients with lung cancer, the high sensitivity and specificity DR-70 can be a biomarker for rapid diagnosis from the blood. Compared with other tumor biomarkers, DR-70 seems to have a better sensitivity and specificity in the diagnosis of lung cancer.